![Georges Gebrael: RWD of Cabozantinib and ICI vs. cabozantinib monotherapy align with CONTACT03 trial results](https://oncodaily.com/pub/uploads/2024/04/IMG_1880-e1712275355345.jpeg)
Photo taken from Georges Gebrael/X
Apr 4, 2024, 20:02
Georges Gebrael: RWD of Cabozantinib and ICI vs. cabozantinib monotherapy align with CONTACT03 trial results
Georges Gebrael, Research Fellow at Huntsman Cancer Institute and University of Utah, shared on X/Twitter:
“Just in ACS Journal Cancer. Patients with clear cell mRCC kidney cancer from real world Flatiron database status post ICI treatment, similar survival with cabozantinib and ICI vs. cabozantinib monoRx aligning with CONTACT03 trial results.”
Source: Georges Gebrael/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 11, 2024, 16:30
Sep 11, 2024, 16:20
Sep 11, 2024, 13:56